Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Victor S. Blanchette, FRCP, Laura Tiseo, BSc, CCRP, David Lillicrap, MD, Shannon Jackson, MD FRCPC, Massimo Morfini, MD, Vanessa Bouskill, MN, Manuel Carcao, Margaret L. Rand, PhD, Derek Stephens, MSc, Liane Khoo, MD, Ester Zapotocka, MD, Vladimir Komrska, MD, Jan Blatny, MD PhD

Blood (2018) 132 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2018-99-111024

Published: 2018

Journal Articles

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Qi Wang, PhD, Sarah F. Cook, Scott A. Van Wart, Donald E. Mager, Stefan Faderl, MD

Blood (2018) 132 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2018-99-111918

Published: 2018

Journal Articles

Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A

Phillip Staibano, BSc, MSc, Alanna McEneny-King, MSc, PhDc), Massimo Morfini, MD, Gary Foster, PhD, Nicholas Hobson, Tamara Navarro-Ruan, MSc, Andrea N Edginton, PhD, Alfonso Iorio, MD PhD

Blood (2017) 130 (Supplement 1): 4934.

https://doi.org/10.1182/blood.V130.Suppl_1.4934.4934

Published: 2017

Journal Articles

Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction

Mina Nikanjam, MD PhD, Edmund Capparelli, PharmD, Jeffrey E. Lancet, MD, Jonathan E. Kolitz, MD, Arthur C. Louie, MD, Gary J. Schiller, MD

Blood (2016) 128 (22): 3955.

https://doi.org/10.1182/blood.V128.22.3955.3955

Published: 2016

Journal Articles

Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia

Patrick T. McGann, MD MS, Min Dong, PhD, Russell E. Ware, MD PhD, Alexander A Vinks, PharmD, PhD

Blood (2015) 126 (23): 982.

https://doi.org/10.1182/blood.V126.23.982.982

Published: 2015

Journal Articles

IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.

Edward D. Gomperts, MD, Shashikant Apte, MD, Utpal Chaudhuri, MD, Joseph M John, MD, Vijay Ramanan, MD, Ri Liesner, MA MBBChir MD FRCP FRCPath MRCPCH, Amy D. Shapiro, MD, Bonnie J. Mills, PhD, Martin Lee, PhD

Blood (2012) 120 (21): 2225.

https://doi.org/10.1182/blood.V120.21.2225.2225

Published: 2012

Journal Articles

Population Pharmacokinetics of Enoxaparin During the Antenatal Period

Jignesh P. Patel, MSc, Bruce Green, D.Clin.Pharm, Raj K. Patel, MD MRCP FRCPath, Michael S. Marsh, MD, J. Graham Davies, PhD, Roopen Arya, PhD

Blood (2012) 120 (21): 503.

https://doi.org/10.1182/blood.V120.21.503.503

Published: 2012

Journal Articles

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Poonkuzhali Balasubramanian, Salamun Desire, M.Sc, John C Panetta, PhD, Kavitha M Lakshmi, MSc, Ezhilpavai Mohanan, M.Sc, Auro Viswabandya, Biju George, MD, Vikram Mathews, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 1941.

https://doi.org/10.1182/blood.V118.21.1941.1941

Published: 2011

Journal Articles

A Mechanism Based Pharmacokinetic/Pharmacodynamic Model of the Effect of a Prolyl Hydroxylase Inhibitor on Erythropoietic Response In Mice

Indrajeet Singh, Wojciech Krzyzanski, Pratap Singh

Blood (2010) 116 (21): 4769.

https://doi.org/10.1182/blood.V116.21.4769.4769

Published: 2010

Journal Articles

Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation.

Sung-Doo Kim, Je-Hwan Lee, Seong-Gil Ryu, Eun-Hye Hur, Mun Jung Kang, Jung-Hee Lee, Dae-Young Kim, Sung-Nam Lim, Young-Shin Lee, Young-Ah Kang, Hyeong-Seok Lim, Kyun Seop Bae, Gyu Jeong Noh, Sung-Cheol Yun, Sang Beom Han, Kyoo-Hyung Lee

Blood (2009) 114 (22): 1179.

https://doi.org/10.1182/blood.V114.22.1179.1179

Published: 2009

Journal Articles

Morphine Pharmacokinetics in Sickle Cell Disease: Implications for Pain Management.

Deepika S. Darbari, Michael Neely, MD, John VandenAnker, MD, Sohail R Rana, MD

Blood (2009) 114 (22): 2574.

https://doi.org/10.1182/blood.V114.22.2574.2574

Published: 2009

Journal Articles

Pharmacokinetics and Dose-Finding of Fragmin in Pediatric Patients at Risk for Thromboembolic Events.

Lesley G. Mitchell, Patricia Massicotte, Patricia Vegh, Peter Cox, Dimple Patel, Castillo Maria, Etches Wai, Stang Linda, Barrett Jeff

Blood (2007) 110 (11): 1861.

https://doi.org/10.1182/blood.V110.11.1861.1861

Published: 2007

Journal Articles

Intraindividual Comparison between Deferasirox and Deferoxamine in Thalassemia.

Roland Fischer, PhD, Regine Grosse, Rainer Engelhardt, PhD, Peter Nielsen, PhD, MD, Oliver Leismann, PhD, Gritta E. Janka, MD

Blood (2007) 110 (11): 2776.

https://doi.org/10.1182/blood.V110.11.2776.2776

Published: 2007

Journal Articles

Single Dose Administration of rFVIIa and NN1731 in Two Hemophilia A Dogs.

Mirella Ezban, Lone Frost, Larsen, Dorthe Viuff, Judi Møss, Mark Kloos, Aaron Dillow, Elizabeth Merricks, Robin Raymer, Timothy C. Nichols

Blood (2007) 110 (11): 3144.

https://doi.org/10.1182/blood.V110.11.3144.3144

Published: 2007

Journal Articles

PEG Modified rVWF Prolongs the Survival of Native rFVIII in Hemophilia A Knock-Out Mice.

Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Herbert Gritsch, PhD, Bernhard Baumgartner, DVM, Katalin Váradi, PhD, H. Peter Matthiessen, PhD, Juergen Siekmann, PhD, Eva-Maria Muchitsch, DVM, Hans Peter Schwarz, MD

Blood (2006) 108 (11): 1002.

https://doi.org/10.1182/blood.V108.11.1002.1002

Published: 2006

Journal Articles

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Jens Hillengass, MD, Christian Zechmann, MD, Andreas Nadler, Stefan Delorme, MD, Axel Benner, Christiane Heiss, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Thomas Moehler, MD

Blood (2006) 108 (11): 5079.

https://doi.org/10.1182/blood.V108.11.5079.5079

Published: 2006

Journal Articles

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Jens Hillengass, MD, Klaus Wasser, MD, Axel Benner, Stefan Delorme, MD, Christian Zechmann, MD, Anthony D. Ho, Hartmut Goldschmidt, Thomas Moehler, MD

Blood (2005) 106 (11): 5062.

https://doi.org/10.1182/blood.V106.11.5062.5062

Published: 2005

Journal Articles

Thrombin Generation Assay: Use in Monitoring Treatment of Patients with Coagulation Factor Inhibitors.

Aine N. McCormick, Ph.D., Peter L. Turecek, Ph.D., Katalin Varadi, Ph.D., Geoffrey F. Savidge

Blood (2004) 104 (11): 3087.

https://doi.org/10.1182/blood.V104.11.3087.3087

Published: 2004

NARROW

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A

Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction

Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia

IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.

Population Pharmacokinetics of Enoxaparin During the Antenatal Period

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

A Mechanism Based Pharmacokinetic/Pharmacodynamic Model of the Effect of a Prolyl Hydroxylase Inhibitor on Erythropoietic Response In Mice

Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation.

Morphine Pharmacokinetics in Sickle Cell Disease: Implications for Pain Management.

Pharmacokinetics and Dose-Finding of Fragmin in Pediatric Patients at Risk for Thromboembolic Events.

Intraindividual Comparison between Deferasirox and Deferoxamine in Thalassemia.

Single Dose Administration of rFVIIa and NN1731 in Two Hemophilia A Dogs.

PEG Modified rVWF Prolongs the Survival of Native rFVIII in Hemophilia A Knock-Out Mice.

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Thrombin Generation Assay: Use in Monitoring Treatment of Patients with Coagulation Factor Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only